Is it time to retire bolus cisplatin? Lessons from the ConCERT trial
JNCI: Journal of the National Cancer Institute · 01.11.2026 · 118 (11) · 2001-2003
DOI: 10.1093/jnci/djag331 ↗Kurz gefasst
Editorial in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 14.10.2026. Verfasst von Ross D Merkin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Mass General Brigham Cancer Institute, Boston, MA, United States. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Mass General Brigham Cancer Institute, Boston, MA, United States.
- Department of Medicine, Massachusetts General Hospital, Boston, MA, United States.
- Massachusetts Eye and Ear, Boston, MA, United States.
- Department of Medicine, Harvard Medical School, Boston, MA, United States.
- Department of Internal Medicine (Medical Oncology), Yale School of Medicine and Yale Cancer Center, New Haven, CT, United States.
ORCID-Profile: Aarti Bhatia
Zitieren
APA
Merkin, R. D., & Bhatia, A. (2026). Is it time to retire bolus cisplatin? Lessons from the ConCERT trial. JNCI: Journal of the National Cancer Institute, 118(11), 2001-2003. https://doi.org/10.1093/jnci/djag331
Vancouver
Merkin RD, Bhatia A. Is it time to retire bolus cisplatin? Lessons from the ConCERT trial. JNCI: Journal of the National Cancer Institute. 2026;118(11):2001-2003. doi:10.1093/jnci/djag331
BibTeX
@article{Merkin2026,
author = {Merkin, Ross D and Bhatia, Aarti},
title = {Is it time to retire bolus cisplatin? Lessons from the ConCERT trial},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2026},
volume = {118},
number = {11},
pages = {2001--2003},
doi = {10.1093/jnci/djag331}
}
EUVIMED